Role of Apathy in the Effectiveness of Weight Loss Interventions
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether treating apathy with methylphenidate or medical Crisis counselling will increase adherence to weight loss programs thereby increasing their effectiveness
| Condition | Intervention |
|---|---|
|
Obesity Apathy |
Behavioral: MOVE Behavioral: medical crisis councelling Drug: methyphenidate |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Role of Apathy in the Effectiveness of Weight Loss Interventions in Obese Patients |
- change in Apathy score and change in Weight (lbs) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- lipids, adherence measures [ Time Frame: 6 months ] [ Designated as safety issue: No ]
| Enrollment: | 125 |
| Study Start Date: | August 2007 |
| Study Completion Date: | May 2009 |
| Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: 1
standard nutrition counselling
|
|
|
Experimental: 2
MOVE -weight loss intervention
|
Behavioral: MOVE
is a VA based multidesciplinary weight loss intervention
|
|
Experimental: 3
MOVE plus medical crisis counselling
|
Behavioral: medical crisis councelling
group counselling sessions
Behavioral: MOVE
is a VA based multidesciplinary weight loss intervention
|
|
Experimental: 4
MOVE plus methylphenidate
|
Drug: methyphenidate
methyphenidate will be used to treat apathy dose 10mg bid
Behavioral: MOVE
is a VA based multidesciplinary weight loss intervention
|
|
Experimental: 5
MOVE plus methyphenidate plus medical crisis counselling
|
Drug: methyphenidate
methyphenidate will be used to treat apathy dose 10mg bid
Behavioral: medical crisis councelling
group counselling sessions
Behavioral: MOVE
is a VA based multidesciplinary weight loss intervention
|
Detailed Description:
Title: The role of Apathy in the effectiveness of weight loss interventions in obese patients
Objective: Obesity is a major public health problem. Apathy is a common behavioral problem characterized by loss of initiative, poor motivation and persistence. Presence of apathy impairs the self-care behavior in obese patients. Lack of novelty might impair a patient's ability to seek new interactions, life styles and new treatment options for obesity. Lack of motivation might impair a patient's ability to initiate exercise regimen or diet whereas lack of persistence impairs the compliance with these regimens. Thus, apathy influences all stages of self-care. We hypothesize that the treatment of apathy will result in better adherence to weight loss interventions in obese veterans enrolled in the MOVE program.
Research Design: A prospective open label randomized study. Group 1 will have patients with obesity as defined as BMI>30, and apathy defined as AES score of > 40. This group will be treated with standard nutrition counseling. Group 2 will have patients with obesity and apathy as defined above and will receive the MOVE enhancement program alone (The MOVE program is a national VA weight loss program). Group 3 will be treated with methylphenidate along with the MOVE enhancement program. Group 4 will be treated with medical crisis counseling along with the MOVE enhancement program. Group 5 will be treated with methylphenidate, and the medical crisis counseling along with the MOVE enhancement program.
Methodology: 30 patients meeting the criteria will be enrolled in each of the five arms. All patients will be in the study for duration of six months. All patients in the methylphenidate arm will be started at 5mg twice daily and titrated to 10mg twice daily at two weeks. Patients will be assessed on regular intervals using the Apathy Evaluation Scale, Hamilton Depression Scale and the Patient activation measure. MOVE sessions will be held once weekly from the 2nd visit to the end of the study. Medical Crisis Counseling visits will be every week for nine sessions and then every other week till the end of the study
Clinical Relationships/Significance: The prevalence of obesity in the general population is over 30%. However the prevalence of obesity in the VA health system is almost 70%. Since obesity predisposes to several co-morbid conditions such as hypertension, diabetes and cardiovascular disease, it is important to develop interventions that are effective in inducing weight loss. Since apathy plays a large role in the self care behaviours that lead to obesity, treating apathy may improve adherence to weight loss programs
Eligibility| Ages Eligible for Study: | 21 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- BMI >30
- Apathy score >40
Exclusion Criteria:
- History of cancer, except basal cell
- Cardiovascular event in last 6 months
- Renal failure
Contacts and Locations
More Information
No publications provided
| Responsible Party: | DeSouza, Cyrus - Principal Investigator, Department of Veterans Affairs |
| ClinicalTrials.gov Identifier: | NCT00548652 History of Changes |
| Other Study ID Numbers: | 00469 |
| Study First Received: | October 23, 2007 |
| Last Updated: | April 7, 2011 |
| Health Authority: | United States: Federal Government |
Keywords provided by Department of Veterans Affairs:
|
apathy obesity methylphenidate MOVE medical crisis counselling |
Additional relevant MeSH terms:
|
Obesity Weight Loss Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms Body Weight Changes Methylphenidate Dopamine Uptake Inhibitors |
Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Neurotransmitter Uptake Inhibitors Physiological Effects of Drugs Central Nervous System Stimulants Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on June 18, 2013